...
首页> 外文期刊>Cytotherapy >Detailed analysis of cytomegalovirus (CMV)-specific T cells expanded for adoptive immunotherapy of CMV infection following allogeneic stem cell transplantation for malignant disease
【24h】

Detailed analysis of cytomegalovirus (CMV)-specific T cells expanded for adoptive immunotherapy of CMV infection following allogeneic stem cell transplantation for malignant disease

机译:同种异体干细胞移植治疗恶性疾病后巨细胞病毒(CMV)特异性T细胞扩增的详细分析,用于CMV感染的过继免疫治疗

获取原文
获取原文并翻译 | 示例

摘要

Background Cytomegalovirus (CMV) infection and its treatment causes significant morbidity following allogeneic stem cell transplantation (SCT) for malignancies. We studied the phenotype, function and growth kinetics of CMV pp65 antigen (Ag)-specific T cells expanded in a short-term culture for adoptive therapy. Methods Peripheral blood mononuclear cells (PBMC) from CMV-seropositive donors were cultured in various conditions with CMV p65((495-503)) peptide to determine the most effective method fir generating CMV-specific T cells. CM V-expanded cultures were tested for frequency, phenotype and functionality using peptide-MHC tetramer analysis, cytokine flow cytometry and cytolytic assays. A patient undergoing allogeneic SCT was administered CMV pp65-specific T cells generated from the donor based on these data, and recipient PBMC were analyzed following T-cell infusion. Results CMV pp65-specific T cells were consistently generated from CMV-seropositive donors at high frequencies (20-40% of CD8(+) T cells),secreted interferon-gamma (IFN-gamma) in response to CMV peptide and bad lytic activity against CMV peptide-expressing targets. Cultured CMV-specific T cells were infused into a SCT recipient without toxicity. Discussion Stimulating donor PBMC to generate functional, Ag-specific T cells for infusion into SCT recipients was accomplished consistently using readily available technology. We observed no toxicity in one patient receiving T cells and were able to monitor infused cells. These findings support further study of ibis approach as a prophylaxis against the risk of infection in patients receiving allogeneic transplantation from CMV-seropositive donors.
机译:背景巨细胞病毒(CMV)感染及其治疗会导致异基因干细胞移植(SCT)致恶性肿瘤的重大发病。我们研究了在短期培养中扩大的CMV pp65抗原(Ag)特异性T细胞的表型,功能和生长动力学,用于过继治疗。方法将CMV血清阳性的供体的外周血单个核细胞(PBMC)与CMV p65((495-503))肽在不同条件下培养,以确定产生CMV特异性T细胞的最有效方法。使用肽-MHC四聚体分析,细胞因子流式细胞仪和溶细胞测定法测试CM V扩增培养物的频率,表型和功能。根据这些数据,对接受同种异体SCT的患者接受从供体产生的CMV pp65特异性T细胞,并在T细胞输注后对受体PBMC进行分析。结果CMV pp65特异性T细胞由CMV血清阳性的供体以高频率(CD8(+)T细胞的20-40%),分泌的干扰素-γ(IFN-γ)稳定地产生,响应于CMV肽和不良的裂解活性对抗表达CMV肽的靶标。将培养的CMV特异性T细胞无毒性地注入SCT受体中。讨论使用现成的技术始终如一地完成了刺激供体PBMC产生功能性,特定于Ag的T细胞以注入SCT受体的过程。我们观察到一位接受T细胞的患者没有毒性,并且能够监测输注的细胞。这些发现支持宜必思方法的进一步研究,该方法可预防从CMV血清反应阳性供体接受同种异体移植的患者的感染风险。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号